<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; WisdomTree SmallCap Dividend</title>
	<atom:link href="http://www.stockbloghub.com/tag/wisdomtree-smallcap-dividend/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BSX) Boston Scientific Corporation Grows US Cardiac Rhythm Management Portfolio</title>
		<link>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918</link>
		<comments>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:29:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87918</guid>
		<description><![CDATA[Boston Scientific Corporation’s (BSX) Cardiac Rhythm Management (CRM) should record higher sales with the US Food and Drug Administration (FDA) approving Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). These devices are meant to treat heart failure and sudden cardiac death. Though expected, the US approval comes even earlier than the company’s original guidance of late 2011 or early 2012. CE Mark approval for these defibrillators was received in the second quarter of 2011. The company is confident of the ready adoption of these devices as they come with improved therapy options, advanced battery longevity and a DF4 universal connector system. The company also announced an extended warranty for these devices in the US and many international countries of up to 10 years. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson to Discontinue Cypher Stent</title>
		<link>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575</link>
		<comments>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575#comments</comments>
		<pubDate>Thu, 16 Jun 2011 21:59:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[El Paso Corporation]]></category>
		<category><![CDATA[EP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76575</guid>
		<description><![CDATA[Cordis Corporation, a Johnson &#38; Johnson (JNJ) company, recently announced that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year end. The company will also discontinue the development of Nevo sirolimus-eluting coronary stent. Cordis intends to focus on other cardiovascular therapies instead. Cypher Sales Were Under Pressure The decision to discontinue Cypher stent does not come as a surprise given the declining sales of the product. Changing dynamics in the drug-eluting stent (DES) market along with unlicensed competition from products infringing Cordis’ patents led to an erosion in Cypher stent’s pricing, sales and market share. Moreover, the launch of superior products by competitors also led to a loss of market share. On the first quarter call, Johnson &#38; Johnson reported a 41% decline in Cypher ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/jnj-johnson-johnson-to-discontinue-cypher-stent/76575/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMS) Medical Devices Industry Outlook &#8211; August 2010 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243</link>
		<comments>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243#comments</comments>
		<pubDate>Wed, 25 Aug 2010 15:14:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Utilities]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49243</guid>
		<description><![CDATA[Prelude The global medical devices industry is fairly large, intensely competitive and highly innovative with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (HCIT). The U.S. medical devices industry continues to grow at a brisk rate, thanks to an aging Baby Boomer population, with Neuro, Orthopedic and Aesthetic representing the fastest growing categories. With several growth constraints in the legacy markets, medical devices companies are aiming to expand into lucrative incipient markets. Expansion in the emerging markets, especially those with double-digit annual growth rates, represents one of the best potential avenues for future growth. Our focus in this write up, however, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/25/cms-medical-devices-industry-outlook-august-2010-zacks-analyst-interviews/49243/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific Corporation Surpasses Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/20/bsx-boston-scientific-corporation-surpasses-estimates/18186</link>
		<comments>http://www.stockbloghub.com/2009/10/20/bsx-boston-scientific-corporation-surpasses-estimates/18186#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:04:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18186</guid>
		<description><![CDATA[Boston Scientific Corporation (BSX) yesterday reported financial results for the third quarter of fiscal 2009 after the market close. Earnings per share were 19 cents, beating the Zacks Consensus Estimate by 5 cents and the year-ago earnings by 3 cents. Sales Net sales in the quarter were $2.0 billion Incorporatedreasing approximately 2% year over year. Excluding an unfavorable foreign currency translation (FX), net sales increased roughly 3% year over year. On a geographic basis, U.S. sales contributed roughly 58% of total revenues and increased 4% year over year. International sales increased 2% year over year. Growth in net sales can be attributed to higher demand for the company’s Cardiac Rhythm Management [CRM], Endosurgery and Neuromodulation products, with revenues increasing 6%, 8%, and 21%, respectively, in these segments. This was partly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/bsx-boston-scientific-corporation-surpasses-estimates/18186/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Lab&#8217;s XIENCE V Presents Positive Data</title>
		<link>http://www.stockbloghub.com/2009/09/22/abt-abbott-labs-xience-v-presents-positive-data/15823</link>
		<comments>http://www.stockbloghub.com/2009/09/22/abt-abbott-labs-xience-v-presents-positive-data/15823#comments</comments>
		<pubDate>Tue, 22 Sep 2009 20:28:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15823</guid>
		<description><![CDATA[Yesterday, Abbott (ABT) presented positive long-term data on the XIENCE V Everolimus Eluting Coronary Stent System from the pivotal SPIRIT III study conducted in the U.S. Results showed that clinical advantages associated with the use of XIENCE V continued to increase compared to Boston Scientific&#8216;s (BSX) Taxus Express2 Paclitaxel-Eluting Coronary Stent System. At three years, XIENCE V demonstrated a reduction in the risk of major adverse cardiac events (9.1% for XIENCE V compared to 15.7% for Taxus). XIENCE V also demonstrated a reduction in the risk of Target Lesion Failure (8.3% for XIENCE V versus 14.4% for Taxus), a reduction in the risk of Target Vessel Failure (13.5% for XIENCE V compared to 19.2% for Taxus) and a reduction in the risk of heart attacks (3.7% for XIENCE V compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/22/abt-abbott-labs-xience-v-presents-positive-data/15823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott&#8217;s Stent Cleared for Immediate Launch in Canada</title>
		<link>http://www.stockbloghub.com/2009/08/25/abt-abbotts-stent-cleared-for-immediate-launch-in-canada/13350</link>
		<comments>http://www.stockbloghub.com/2009/08/25/abt-abbotts-stent-cleared-for-immediate-launch-in-canada/13350#comments</comments>
		<pubDate>Tue, 25 Aug 2009 20:34:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13350</guid>
		<description><![CDATA[Yesterday, Abbott Laboratories (ABT) received approval from Health Canada for its XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD). The product will be launched in Canada immediately. Coronary artery disease is a common type of heart disease in which plaque buildup narrows the arteries and reduces blood flow to the heart. This can lead to chest pain or a heart attack. XIENCE V is a drug coated stent that is used to treat CAD by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner over time so as to help prevent the artery from getting blocked again. XIENCE V is currently available in the United States, Europe and other international markets. Shortly after its 2008 approval ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/abt-abbotts-stent-cleared-for-immediate-launch-in-canada/13350/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

